Adenosine Receptors and Parkinson's Disease

Hiroshi Kase, Peter J. Richardson, Peter Jenner

Elsevier Science, Oct 15, 1999 - Medical - 275 pages

This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.

• Discusses the discovery and development of a novel non-dopaminomimetic agent for Parkinson's disease
• Provides the first definitive overview of adenosine antagonists and their role in the treatment of Parkinson's disease
• Presents a new mechanism of action of adenosine A2A receptor antagonists in motor function Proposes a hypothesis of adenosine A2A receptor function in the striatum
• Comprehensive overview of adenosine, its receptor subtypes, their antagonists/agonists from biochemistry, molecular biology, medicinal chemistry, physiology, pharmacology, and neurochemistry viewpoints

About the author

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson's disease. He has spent the major part of his career at King's College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King's College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson's disease patient-carer groups across the UK.

Bibliographic information

• Title: Adenosine Receptors and Parkinson's Disease; Volume 60 of Pure and applied mathematics
• Editors: Hiroshi Kase, Peter J. Richardson, Peter Jenner
• Edition: illustrated
• Publisher: Elsevier Science, 1999
• ISBN: 0124004059, 9780124004054
• Length: 275 pages
• Subjects: Medical / Biochemistry; Medical / Neurology; Medical / Neuroscience; Medical / Pharmacology; Medical / Pharmacy; Science / Life Sciences / Biochemistry; Science / Life Sciences / Neuroscience